Back Login to subscribe 🔔 Set Alert

RNXT RenovoRx, Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5	87.15%
	RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.	94.2%
	12 Health Care Stocks Moving In Tuesday's Intraday Session	96.91%
	RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure	79.24%
	RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of Cancer	56.87%
	12 Health Care Stocks Moving In Wednesday's After-Market Session	96.2%
	RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est	94.24%
	RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate	69.25%
	EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027	95.02%
	EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027	67.44%

1
2
›